David A Cairns
Overview
Explore the profile of David A Cairns including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
2296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaiser M, Sonneveld P, Cairns D, Raab M, San-Miguel Izquierdo J, Zhang R, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401253.
PMID: 39965171
Purpose: Survival for patients with multiple myeloma (MM) has improved but outcomes remain heterogeneous. Consistent diagnostic identification of high-risk disease is desirable to address unmet patient need. The aim was...
2.
Pearce J, Martin S, Heritage S, Khoury E, Kucharczak J, Nuamek T, et al.
J Natl Cancer Inst
. 2025 Jan;
PMID: 39886936
Background: It is increasingly recognised that frailty should be assessed and considered in treatment decision-making in patients with cancer. This review and meta-analysis synthesises existing evidence evaluating the association between...
3.
Cook G, Ashcroft A, Senior E, Olivier C, Hockaday A, Richards J, et al.
Lancet Haematol
. 2024 Sep;
11(11):e816-e829.
PMID: 39250926
Background: The efficacy of consolidation and maintenance in the context of salvage autologous haematopoietic stem-cell transplantation (HSCT) for relapsed multiple myeloma remains unclear. We aimed to assess whether consolidation after...
4.
Pawlyn C, Schjesvold F, Cairns D, Wei L, Davies F, Nadeem O, et al.
Blood Cancer J
. 2024 Aug;
14(1):134.
PMID: 39134544
Measurement of overall survival (OS) remains the gold standard for interpreting the impact of new therapies for multiple myeloma in phase 3 trials. However, as outcomes have improved, it is...
5.
De Tute R, Cook G, Cairns D, Brown J, Cavenagh J, Ashcroft A, et al.
Bone Marrow Transplant
. 2024 Jan;
59(3):431-434.
PMID: 38195983
No abstract available.
6.
Munir T, Cairns D, Bloor A, Allsup D, Cwynarski K, Pettitt A, et al.
N Engl J Med
. 2023 Dec;
390(4):326-337.
PMID: 38078508
Background: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment...
7.
Hull M, Loo Ow P, Ruddock S, Brend T, Smith A, Marshall H, et al.
BMJ Open
. 2023 Nov;
13(11):e077427.
PMID: 38030258
Introduction: There remains an unmet need for safe and cost-effective adjunctive treatment of advanced colorectal cancer (CRC). The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) is safe, well-tolerated and has...
8.
Royle K, Meads D, Visser-Rogers J, White I, Cairns D
Trials
. 2023 Nov;
24(1):708.
PMID: 37926806
Background: Overall survival is the "gold standard" endpoint in cancer clinical trials. It plays a key role in determining the clinical- and cost-effectiveness of a new intervention and whether it...
9.
Jones J, Cairns D, Menzies T, Pawlyn C, Davies F, Sigsworth R, et al.
EClinicalMedicine
. 2023 Aug;
62:102099.
PMID: 37554123
Background: Early trials of long-term lenalidomide use reported an increased incidence of second primary malignancy (SPM), including acute myeloid leukaemia and myelodysplastic syndrome. Later, meta-analysis suggested the link to be...
10.
McNamara M, Swain J, Craig Z, Sharma R, Faluyi O, Wadsley J, et al.
EClinicalMedicine
. 2023 Jun;
60:102015.
PMID: 37287870
Background: The prognosis for patients with poorly-differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) is poor. A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy with no standard second-line (2L) treatment....